Evidence map›Paper›PMID 36704614›Full record

Observational studyInternational journal of chronic obstructive pulmonary disease2023

Real-World Evidence on the Diagnostic and Clinical Characteristics of Asthma in Japanese Patients with COPD: The ACO Japan Cohort Study.

Shu Hashimoto, Yuri Yoshida, Naoyuki Makita, Ryoko Sorimachi, Satoko Sugaya, Yoshifumi Arita, Nobuya Hayashi, Naoki Tashiro, Masakazu Ichinose

Open access · goldAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in International journal of chronic obstructive pulmonary disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Differential Clinical Significance of FENOJournal of asthma and allergy · 2024
    Article
  10. Underdiagnosis of COPD: The Japan COPD Real-World Data Epidemiological (CORE) Study.International journal of chronic obstructive pulmonary disease · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Shu HashimotoNihon University, Tokyo, Japan.
Yuri YoshidaMedical Department, AstraZeneca K.K., Osaka, Japan.
Naoyuki MakitaMedical Department, AstraZeneca K.K., Osaka, Japan.
Ryoko SorimachiMedical Department, AstraZeneca K.K., Osaka, Japan.
Satoko SugayaR&D, AstraZeneca K.K., Osaka, Japan.
Yoshifumi AritaMedical Department, AstraZeneca K.K., Osaka, Japan.
Nobuya HayashiR&D, AstraZeneca K.K., Osaka, Japan.ORCID 0000-0002-5386-5599
Naoki TashiroMedical Department, AstraZeneca K.K., Osaka, Japan.
Masakazu IchinoseAcademic Center of Osaki Citizen Hospital, Miyagi, Japan.
AstraZeneca (Japan) · JPNihon University · JPTohoku University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The ACO Japan Cohort Study, a multicenter observational study, investigated the proportion of patients with chronic obstructive pulmonary disease (COPD) who met the Japanese Respiratory Society (JRS) asthma-COPD overlap (ACO) diagnostic criteria, characteristics of ACO and non-ACO patients, and the patient transitions between ACO/non-ACO diagnosis over 2 years. Patients and Methods: Patients with COPD were consecutively enrolled between June and December 2018 and followed up continuously for 2 years. All participating study sites were medical institutions where respiratory specialists routinely conducted medical examinations/tests required for ACO diagnosis. Results: Among 708 patients with COPD, 101 (14.3%), 118 (16.7%), and 125 (17.7%) were diagnosed with ACO at registration, 1 year, and 2 years, respectively. In total, 22.6% of patients lacked the data necessary for ACO diagnosis throughout the 2 years. Among patients who had the necessary data for ACO diagnosis, 24.7% were diagnosed with ACO at 2 years. More ACO patients had moderate or severe exacerbations in the past year than non-ACO patients at registration (15.8% vs 6.3%, p = 0.049) and 1 year (19.4% vs 7.6%, p = 0.025). ACO patients had a greater decrease in mean forced expiratory volume in one second over 2 years than non-ACO patients (-92.0 vs 43.4 mL). Among patients diagnosed with ACO at registration, 21.4% transitioned to non-ACO after 1 year. Conversely, almost all non-ACO patients at registration remained non-ACO after 1 year. Conclusion: COPD patients with ACO determined by the JRS criteria had a high risk of exacerbations and a rapid decline in respiratory function, indicating that the JRS criteria for ACO are useful for identifying high-risk COPD patients. Testing necessary for ACO diagnosis is insufficiently performed even in real-world clinical practice of COPD specialists.

Indexed as

AsthmaPulmonary Disease, Chronic ObstructiveCohort StudiesEast Asian PeopleForced Expiratory VolumeHumansJapanasthmachronic obstructive pulmonary diseaseexacerbationFEV1 declineinhaled corticosteroid

Identifiers

PMID36704614
PMCPMC9871028
OpenAlexW4317213999

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.